Business
CytoSorbents to Report Fiscal 2022 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9, 2023 at 4:30PM EST.\n\n \n \n \n \n \n \n\n \nCytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2022 and fiscal year ending December 31, 2022 followed by a question and answer session.\nConference Call Details:\nDate: Thursday, March 9, 2023Time: 4:30 PM EasternParticipant Dial-In: 201-389-0879Conference ID: 13736064 Live Presentation Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1596520&tp_key=3635996201\nIt is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: \nhttps://viavid.webcasts.com/starthere.jsp?ei=1596520&tp_key=3635996201\nAn archived recording and written transcript of the conference call will be available under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/\nAbout CytoSorbents Corporation (NASDAQ: CTSO) \nCytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces \"cytokine storm\" or \"cytokine release syndrome\" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. At the end of 2022, more than 195,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Add...